Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 3/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.33 |
| ▸ | PDE4A | P27815 | 2/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.33 |
| ▸ | ACACB | O00763 | 1/20 | 0.30 |
| ▸ | APP | P05067 | 1/20 | 0.30 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13586560 | 0.94 | PDE4B (0.33) | FPR2PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL12717094 | 0.90 | FPR2 (0.36) | FPR2PDE4BACACBAPPCNR2 | |
| SCHEMBL12716540 | 0.89 | PDE4B (0.33) | FPR2PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL12821168 | 0.89 | PDE4B (0.33) | FPR2PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL12717399 | 0.88 | KDM1A (0.38) | FPR2PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL12821171 | 0.88 | PDE4B (0.32) | FPR2PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL12907064 | 0.87 | FPR2 (0.33) | FPR2PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL12823188 | 0.86 | FPR2 (0.35) | FPR2PDE4B | |
| SCHEMBL13586577 | 0.86 | APP (0.33) | FPR2PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL12823365 | 0.85 | PDE4A (0.32) | PDE4BPDE4APDE4CPDE4DAPP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110090450-A1 | FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110090450-A1 | FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | LEF1, LAS1L, EFHD2 | FPR2 589/4885PDE4B 2984/4885PDE4A 3366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.